Novo Nordisk A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NONOF research report →
About the company
Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Its extensive operations are primarily structured into two distinct divisions: Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment offers comprehensive solutions, encompassing various insulin preparations, GLP-1 receptor agonists along with their delivery systems, oral antidiabetic medications, treatments for weight management, and therapies addressing other chronic health conditions.
- CEO
- Maziar Mike Doustdar
- IPO
- 2010
- Employees
- 77,406
- HQ
- Bagsvaerd, DK
Price Chart
- Market Cap
- $218.13B
- P/E
- 11.91
- P/S
- 4.43
- P/B
- 7.15
- EV/EBITDA
- 8.87
- Div Yield
- 3.58%
- Gross Margin
- 81.85%
- Op Margin
- 45.30%
- Net Margin
- 37.20%
- ROE
- 66.36%
- ROIC
- 32.20%
- Revenue
- $308.36B · 6.18%
- Net Income
- $102.20B · 1.20%
- EPS
- $23.00 · 1.41%
- Op Income
- $134.71B
- FCF YoY
- -15.55%
- 52W High
- $72.61
- 52W Low
- $34.00
- 50D MA
- $44.29
- 200D MA
- $47.70
- Beta
- 0.35
- Avg Volume
- 58.53K
Get TickerSpark's AI analysis on NONOF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NONOF coverage
Recent articles, reports, and earnings notes.
No research on NONOF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NONOF report →Similar companies
Peers in the same neighborhood.